Comparative efficacy of antibody-drug conjugates and chemotherapy for malignant tumors: a systematic review and meta-analysis.

ABSTRACT:

Background

Despite advancements in cancer treatment, malignant tumors remain a significant global health challenge. Drawbacks of chemotherapy, such as drug resistance and strong side effects, have prompted the exploration of antibody-drug conjugates (ADCs), which combine targeting capabilities with potent cytotoxins to enhance therapeutic efficacy.

Methods

We searched PubMed, Cochrane, and EMBASE library databases up to June 8, 2025, for eligible randomized controlled trials (RCTs) and extracted relevant data. The primary outcome measures were overall survival (OS) and progression-free survival (PFS), with subgroup analysis and sensitivity analysis conducted to assess the heterogeneity of statistical results.

Results

A total of thirteen RCTs involving 5,927 patients w

SUBMITTER: Gao X 

PROVIDER: S-EPMC12827071 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature